MYC and in situ carcinoma: As discussed, there is overwhelming evidence that MYC is commonly dysregulated in PIN, carcinoma in situ (CIS) and metastatic, therapy-resistant CRPC by acting at least in part via increasing ribosome biogenesis in the cell.